Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 101

Published Date: 10 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.

According to our (Global Info Research) latest study, the global Dendritic Cell Cancer Vaccine Immunotherapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Dendritic Cell Cancer Vaccine Immunotherapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Dendritic Cell Cancer Vaccine Immunotherapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Dendritic Cell Cancer Vaccine Immunotherapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Dendritic Cell Cancer Vaccine Immunotherapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Dendritic Cell Cancer Vaccine Immunotherapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Dendritic Cell Cancer Vaccine Immunotherapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Dendritic Cell Cancer Vaccine Immunotherapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lineage Cell Therapeutics, AVAX Technologies, DCPrime, Gradalis and Heat Biologics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Dendritic Cell Cancer Vaccine Immunotherapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Provenge
    Apceden
    CreaVax
    Others

Market segment by Application
    Pediatrics
    Adults

Market segment by players, this report covers
    Lineage Cell Therapeutics
    AVAX Technologies
    DCPrime
    Gradalis
    Heat Biologics
    ImmunoCellular Therapeutics
    Immunicum
    MolecuVax
    Northwest Biotherapeutics
    Pique Therapeutics
    Regeneus
    Tessa Therapeutics
    Vaccinogen
    XEME Biopharma

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Dendritic Cell Cancer Vaccine Immunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Dendritic Cell Cancer Vaccine Immunotherapy, with revenue, gross margin and global market share of Dendritic Cell Cancer Vaccine Immunotherapy from 2018 to 2023.
Chapter 3, the Dendritic Cell Cancer Vaccine Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Dendritic Cell Cancer Vaccine Immunotherapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Dendritic Cell Cancer Vaccine Immunotherapy.
Chapter 13, to describe Dendritic Cell Cancer Vaccine Immunotherapy research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccine Immunotherapy
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Dendritic Cell Cancer Vaccine Immunotherapy by Type
        1.3.1 Overview: Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type in 2022
        1.3.3 Provenge
        1.3.4 Apceden
        1.3.5 CreaVax
        1.3.6 Others
    1.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market by Application
        1.4.1 Overview: Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Pediatrics
        1.4.3 Adults
    1.5 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size & Forecast
    1.6 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast by Region
        1.6.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region, (2018-2029)
        1.6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2018-2029)
        1.6.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2018-2029)
        1.6.6 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Lineage Cell Therapeutics
        2.1.1 Lineage Cell Therapeutics Details
        2.1.2 Lineage Cell Therapeutics Major Business
        2.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.1.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Lineage Cell Therapeutics Recent Developments and Future Plans
    2.2 AVAX Technologies
        2.2.1 AVAX Technologies Details
        2.2.2 AVAX Technologies Major Business
        2.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.2.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 AVAX Technologies Recent Developments and Future Plans
    2.3 DCPrime
        2.3.1 DCPrime Details
        2.3.2 DCPrime Major Business
        2.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.3.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 DCPrime Recent Developments and Future Plans
    2.4 Gradalis
        2.4.1 Gradalis Details
        2.4.2 Gradalis Major Business
        2.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.4.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Gradalis Recent Developments and Future Plans
    2.5 Heat Biologics
        2.5.1 Heat Biologics Details
        2.5.2 Heat Biologics Major Business
        2.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.5.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Heat Biologics Recent Developments and Future Plans
    2.6 ImmunoCellular Therapeutics
        2.6.1 ImmunoCellular Therapeutics Details
        2.6.2 ImmunoCellular Therapeutics Major Business
        2.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 ImmunoCellular Therapeutics Recent Developments and Future Plans
    2.7 Immunicum
        2.7.1 Immunicum Details
        2.7.2 Immunicum Major Business
        2.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.7.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Immunicum Recent Developments and Future Plans
    2.8 MolecuVax
        2.8.1 MolecuVax Details
        2.8.2 MolecuVax Major Business
        2.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 MolecuVax Recent Developments and Future Plans
    2.9 Northwest Biotherapeutics
        2.9.1 Northwest Biotherapeutics Details
        2.9.2 Northwest Biotherapeutics Major Business
        2.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Northwest Biotherapeutics Recent Developments and Future Plans
    2.10 Pique Therapeutics
        2.10.1 Pique Therapeutics Details
        2.10.2 Pique Therapeutics Major Business
        2.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Pique Therapeutics Recent Developments and Future Plans
    2.11 Regeneus
        2.11.1 Regeneus Details
        2.11.2 Regeneus Major Business
        2.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Regeneus Recent Developments and Future Plans
    2.12 Tessa Therapeutics
        2.12.1 Tessa Therapeutics Details
        2.12.2 Tessa Therapeutics Major Business
        2.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Tessa Therapeutics Recent Developments and Future Plans
    2.13 Vaccinogen
        2.13.1 Vaccinogen Details
        2.13.2 Vaccinogen Major Business
        2.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 Vaccinogen Recent Developments and Future Plans
    2.14 XEME Biopharma
        2.14.1 XEME Biopharma Details
        2.14.2 XEME Biopharma Major Business
        2.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
        2.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2018-2023)
        2.14.5 XEME Biopharma Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Dendritic Cell Cancer Vaccine Immunotherapy by Company Revenue
        3.2.2 Top 3 Dendritic Cell Cancer Vaccine Immunotherapy Players Market Share in 2022
        3.2.3 Top 6 Dendritic Cell Cancer Vaccine Immunotherapy Players Market Share in 2022
    3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market: Overall Company Footprint Analysis
        3.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Market: Region Footprint
        3.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Type Footprint
        3.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application (2018-2023)
    5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2029)
    6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2029)
    6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        6.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2029)
        6.3.2 United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        6.3.3 Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        6.3.4 Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2029)
    7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2029)
    7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        7.3.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2029)
        7.3.2 Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        7.3.3 France Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        7.3.5 Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        7.3.6 Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region
        8.3.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2018-2029)
        8.3.2 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        8.3.3 Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        8.3.4 South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        8.3.5 India Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        8.3.7 Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2029)
    9.2 South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2029)
    9.3 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        9.3.1 South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2029)
        9.3.2 Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        9.3.3 Argentina Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
        10.3.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2029)
        10.3.2 Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)
        10.3.4 UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
    11.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
    11.3 Dendritic Cell Cancer Vaccine Immunotherapy Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Chain
    12.2 Dendritic Cell Cancer Vaccine Immunotherapy Upstream Analysis
    12.3 Dendritic Cell Cancer Vaccine Immunotherapy Midstream Analysis
    12.4 Dendritic Cell Cancer Vaccine Immunotherapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Lineage Cell Therapeutics Company Information, Head Office, and Major Competitors
    Table 6. Lineage Cell Therapeutics Major Business
    Table 7. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 8. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Lineage Cell Therapeutics Recent Developments and Future Plans
    Table 10. AVAX Technologies Company Information, Head Office, and Major Competitors
    Table 11. AVAX Technologies Major Business
    Table 12. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 13. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. AVAX Technologies Recent Developments and Future Plans
    Table 15. DCPrime Company Information, Head Office, and Major Competitors
    Table 16. DCPrime Major Business
    Table 17. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 18. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. DCPrime Recent Developments and Future Plans
    Table 20. Gradalis Company Information, Head Office, and Major Competitors
    Table 21. Gradalis Major Business
    Table 22. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 23. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Gradalis Recent Developments and Future Plans
    Table 25. Heat Biologics Company Information, Head Office, and Major Competitors
    Table 26. Heat Biologics Major Business
    Table 27. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 28. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Heat Biologics Recent Developments and Future Plans
    Table 30. ImmunoCellular Therapeutics Company Information, Head Office, and Major Competitors
    Table 31. ImmunoCellular Therapeutics Major Business
    Table 32. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 33. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. ImmunoCellular Therapeutics Recent Developments and Future Plans
    Table 35. Immunicum Company Information, Head Office, and Major Competitors
    Table 36. Immunicum Major Business
    Table 37. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 38. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Immunicum Recent Developments and Future Plans
    Table 40. MolecuVax Company Information, Head Office, and Major Competitors
    Table 41. MolecuVax Major Business
    Table 42. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 43. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. MolecuVax Recent Developments and Future Plans
    Table 45. Northwest Biotherapeutics Company Information, Head Office, and Major Competitors
    Table 46. Northwest Biotherapeutics Major Business
    Table 47. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 48. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Northwest Biotherapeutics Recent Developments and Future Plans
    Table 50. Pique Therapeutics Company Information, Head Office, and Major Competitors
    Table 51. Pique Therapeutics Major Business
    Table 52. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 53. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Pique Therapeutics Recent Developments and Future Plans
    Table 55. Regeneus Company Information, Head Office, and Major Competitors
    Table 56. Regeneus Major Business
    Table 57. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 58. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Regeneus Recent Developments and Future Plans
    Table 60. Tessa Therapeutics Company Information, Head Office, and Major Competitors
    Table 61. Tessa Therapeutics Major Business
    Table 62. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 63. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Tessa Therapeutics Recent Developments and Future Plans
    Table 65. Vaccinogen Company Information, Head Office, and Major Competitors
    Table 66. Vaccinogen Major Business
    Table 67. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 68. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 69. Vaccinogen Recent Developments and Future Plans
    Table 70. XEME Biopharma Company Information, Head Office, and Major Competitors
    Table 71. XEME Biopharma Major Business
    Table 72. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product and Solutions
    Table 73. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 74. XEME Biopharma Recent Developments and Future Plans
    Table 75. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue (USD Million) by Players (2018-2023)
    Table 76. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Players (2018-2023)
    Table 77. Breakdown of Dendritic Cell Cancer Vaccine Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 78. Market Position of Players in Dendritic Cell Cancer Vaccine Immunotherapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 79. Head Office of Key Dendritic Cell Cancer Vaccine Immunotherapy Players
    Table 80. Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Type Footprint
    Table 81. Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Application Footprint
    Table 82. Dendritic Cell Cancer Vaccine Immunotherapy New Market Entrants and Barriers to Market Entry
    Table 83. Dendritic Cell Cancer Vaccine Immunotherapy Mergers, Acquisition, Agreements, and Collaborations
    Table 84. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (USD Million) by Type (2018-2023)
    Table 85. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Share by Type (2018-2023)
    Table 86. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Forecast by Type (2024-2029)
    Table 87. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2023)
    Table 88. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Forecast by Application (2024-2029)
    Table 89. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2023) & (USD Million)
    Table 90. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2024-2029) & (USD Million)
    Table 91. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2023) & (USD Million)
    Table 92. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2024-2029) & (USD Million)
    Table 93. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2023) & (USD Million)
    Table 94. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2024-2029) & (USD Million)
    Table 95. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2023) & (USD Million)
    Table 96. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2024-2029) & (USD Million)
    Table 97. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2023) & (USD Million)
    Table 98. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2024-2029) & (USD Million)
    Table 99. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2023) & (USD Million)
    Table 100. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2024-2029) & (USD Million)
    Table 101. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2023) & (USD Million)
    Table 102. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2024-2029) & (USD Million)
    Table 103. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2023) & (USD Million)
    Table 104. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2024-2029) & (USD Million)
    Table 105. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2018-2023) & (USD Million)
    Table 106. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2024-2029) & (USD Million)
    Table 107. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2023) & (USD Million)
    Table 108. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2024-2029) & (USD Million)
    Table 109. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2023) & (USD Million)
    Table 110. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2024-2029) & (USD Million)
    Table 111. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2023) & (USD Million)
    Table 112. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2024-2029) & (USD Million)
    Table 113. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2018-2023) & (USD Million)
    Table 114. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type (2024-2029) & (USD Million)
    Table 115. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2018-2023) & (USD Million)
    Table 116. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Application (2024-2029) & (USD Million)
    Table 117. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2018-2023) & (USD Million)
    Table 118. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Country (2024-2029) & (USD Million)
    Table 119. Dendritic Cell Cancer Vaccine Immunotherapy Raw Material
    Table 120. Key Suppliers of Dendritic Cell Cancer Vaccine Immunotherapy Raw Materials
List of Figures
    Figure 1. Dendritic Cell Cancer Vaccine Immunotherapy Picture
    Figure 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type in 2022
    Figure 4. Provenge
    Figure 5. Apceden
    Figure 6. CreaVax
    Figure 7. Others
    Figure 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 9. Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application in 2022
    Figure 10. Pediatrics Picture
    Figure 11. Adults Picture
    Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 14. Global Market Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 15. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Region (2018-2029)
    Figure 16. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Region in 2022
    Figure 17. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 18. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 19. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 20. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 21. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 22. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Share by Players in 2022
    Figure 23. Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 24. Global Top 3 Players Dendritic Cell Cancer Vaccine Immunotherapy Market Share in 2022
    Figure 25. Global Top 6 Players Dendritic Cell Cancer Vaccine Immunotherapy Market Share in 2022
    Figure 26. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Share by Type (2018-2023)
    Figure 27. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Type (2024-2029)
    Figure 28. Global Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Share by Application (2018-2023)
    Figure 29. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Application (2024-2029)
    Figure 30. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type (2018-2029)
    Figure 31. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application (2018-2029)
    Figure 32. North America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Country (2018-2029)
    Figure 33. United States Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 34. Canada Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 35. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 36. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type (2018-2029)
    Figure 37. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application (2018-2029)
    Figure 38. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Country (2018-2029)
    Figure 39. Germany Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 40. France Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 41. United Kingdom Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 42. Russia Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 43. Italy Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 44. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type (2018-2029)
    Figure 45. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application (2018-2029)
    Figure 46. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Region (2018-2029)
    Figure 47. China Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 48. Japan Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 49. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 50. India Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 51. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 52. Australia Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 53. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type (2018-2029)
    Figure 54. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application (2018-2029)
    Figure 55. South America Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Country (2018-2029)
    Figure 56. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 57. Argentina Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 58. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Type (2018-2029)
    Figure 59. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Application (2018-2029)
    Figure 60. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Country (2018-2029)
    Figure 61. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 62. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 63. UAE Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2018-2029) & (USD Million)
    Figure 64. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
    Figure 65. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
    Figure 66. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of Dendritic Cell Cancer Vaccine Immunotherapy in 2022
    Figure 69. Manufacturing Process Analysis of Dendritic Cell Cancer Vaccine Immunotherapy
    Figure 70. Dendritic Cell Cancer Vaccine Immunotherapy Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Lineage Cell Therapeutics
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
ImmunoCellular Therapeutics
Immunicum
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma

Related Reports

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026

date 01 Apr 2021

date Pharma & Healthcare

The Dendritic Cell Cancer Vaccine Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

date 14 Jan 2022

date Pharma & Healthcare

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2023-2029

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2023-2029

date 23 Jan 2023

date Pharma & Healthcare

The global Dendritic Cell Cancer Vaccine Immunotherapy market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Dendritic Cell Cancer Vaccine Immunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 04 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Dendritic Cell Cancer Vaccine Immunotherapy market size was valued at USD 640 million in 2023 and is forecast to a readjusted size of USD 1220.9 million by 2030 with a CAGR of 9.7% during review period.

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2024-2030

Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2024-2030

date 29 Feb 2024

date Pharma & Healthcare

The global Dendritic Cell Cancer Vaccine Immunotherapy market size is expected to reach $ 1220.9 million by 2030, rising at a market growth of 9.7% CAGR during the forecast period (2024-2030).

Product Tags

dendritic cell cancer vaccine immunotherapy

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>